Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 21.75
Bid: 21.50
Ask: 22.00
Change: -1.05 (-4.61%)
Spread: 0.50 (2.33%)
Open: 22.75
High: 22.00
Low: 21.75
Yest. Close: 22.80
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Scancell Signs SCIB1 Vaccine Manufacturing Deal With Eurogentec

21 Jul 16 08:32

Scancell granted product licence extension from Ichor Medical Systems

(ShareCast News) - Scancell, the developer of immunotherapies for cancer treatments, was granted a product licence option extension from Ichor Medical Systems. The extension is to licence the commercial use of Ichor's TriGrid electroporation delivery system with SCIB1, Scancell's ImmunoBody vaccine,

20 Jul 16 12:35

Scancell Licence To Use TriGrid Technology Extended To 2018 (ALLISS)

20 Jul 16 08:30

Scancell Says Review Supporting Potential Of Moditope Published

13 Jul 16 09:19

Scancell Holdings SCIB1 Cancer Drug Shows "Compelling" Survival Data

6 Jul 16 08:28

Scancell suspends dosing with current supplies of SCIB1 for melanoma

(ShareCast News) - Shares in drug developer Scancell Holdings plunged almost 17% after it suspending dosing with current clinical trial supplies of SCIB1 for melanoma with immediate effect. Patients would be notified as soon as possible. AIM-quoted Scancell said quality-control analysis showed the

17 Jun 16 12:24

WINNERS & LOSERS SUMMARY: National Grid Hit By Break-Up Recommendation

17 Jun 16 09:46

UPDATE 1-Scancell slumps as drug problem disrupts melanoma trial

(Adds latest shares, details) LONDON, June 17 (Reuters) - British drug developer Scancell has suspended dosing in a cancer clinical trial because of quality problems with an immunotherapy treatment, wiping more than a quarter off the value of its shares on Friday. The company said te

17 Jun 16 08:10

BUZZ-Scancell: drug problem spurs worst day in 3 yrs

** Drug developer Scancell's shares down 27 pct, worst day in nearly three years, after suspends dosing in a cancer clinical trial because of quality problems with its immunotherapy treatment SCIB1 ** Co says current supplies of drug no longer meet original specification and are no longer s

17 Jun 16 07:46

Drug problem forces Scancell to suspend cancer trial dosing

LONDON, June 17 (Reuters) - British drug developer Scancell said on Friday it was suspending dosing in a cancer clinical trial because of quality problems with its immunotherapy treatment SCIB1. The company said tests showed the product, which is being assessed for melanoma, was "no longer

17 Jun 16 06:51

Scancell Holdings Suspends Dosing In SCIB1 Cancer Treatment Trials

17 Jun 16 06:44

Scancell's ImmunoBody Platform Chosen For Preclinical Glioma Study

2 Jun 16 07:57

CORRECT (18/05): Scancell Shuffles Board As New US Offices Open

19 May 16 05:55

BROKER RATINGS SUMMARY: Goldman Upgrades Booker, Panmure Cuts Meggitt

18 May 16 08:31

Scancell Shuffles Board As New US Offices Open, Plans For Oxford Base

18 May 16 08:06

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.